5-Amino-1MQ and AOD-9604 are sold side by side as fat-loss compounds, and comparisons treat them as two versions of the same thing. They are not the same kind of thing at all. AOD-9604 is a fragment of human growth hormone that went through a sponsor's trial programme before obesity development stopped; 5-Amino-1MQ is a small synthetic molecule, not a peptide, that blocks an enzyme and has never been given to a person in any published study. This page sets the two records side by side — what each source states, the scale of the figures that circulate, and how those figures look on a syringe (sources opened 2026-10-26). It reports figures; it suggests none.
The full single-compound records are on 5-Amino-1MQ dosage and AOD-9604 dosage. Vial arithmetic for any volume is in the calculators for 5-Amino-1MQ and AOD-9604.
Side by side
| 5-Amino-1MQ | AOD-9604 | |
|---|---|---|
| What it is | Small-molecule quinolinium cation; NNMT inhibitor | 16-residue fragment of human growth hormone (177–191 plus tyrosine) |
| Molecular weight (PubChem) | 159.21 (cation); 286.11 as the iodide salt | 1,815.1 |
| Human dosing record | None | Six sponsor trials, 893 subjects, oral and IV only |
| Animal figure | 5 and 10 mg/kg in aged mice (2019) | 500 mcg/kg by mouth in rats for 19 days (2000) |
| PubMed, 2026-10-26 | 3 records | 23 records |
| ClinicalTrials.gov / DailyMed, 2026-10-26 | 0 / 0 | 0 / 0 |
| Circulating figure (2026-09-18) | 2.5–5 mg injected daily; 50–150 mg by mouth | 250–500 mcg injected daily, often 300 mcg |
| Forms sold | 50 and 100 mg vials; capsules | 2, 5 and 10 mg vials |
The row that separates them most is the human record. AOD-9604's is old, sponsor-run and limited to two routes nobody now uses; 5-Amino-1MQ's is empty.
What each record holds
AOD-9604. Metabolic Pharmaceuticals of Melbourne ran six double-blind placebo-controlled trials between 2001 and 2006: two intravenous studies with single infusions of 25 to 400 mcg/kg, and four oral studies ranging from single doses of 9 to 54 mg up to 0.25 to 1 mg tablets daily for 24 weeks in 502 adults. The published summary (Stier, Vos and Kenley 2013) reports safety: IGF-1 did not change at any dose and glucose tolerance did not worsen. It does not report the weight results of the two long studies, and the obesity programme stopped in February 2007, as recorded on this site's AOD-9604 pages. No trial injected it under the skin. The rat study behind the fragment's fat-metabolism claim gave 500 mcg/kg by mouth for 19 days.
5-Amino-1MQ. The three PubMed records naming it are a 2024 bladder-cancer study in mice, a 2022 study of the gut microbiome in diet-induced obese mice and a 2021 cell-proliferation study. The dose figures quoted for it come from the laboratory that developed the class of NNMT inhibitors: aged mice given 5 and 10 mg/kg after a muscle injury, with stronger regenerated muscle. The 2018 paper that put the class forward for obesity reported lower body weight and fat mass in obese mice without a change in food intake. No registry holds a human study.
Mass and molecule count
The circulating amounts look like they sit on one scale: hundreds of micrograms for AOD-9604, a few milligrams for 5-Amino-1MQ. The molecules are not on one scale. AOD-9604 weighs about 1,815 per mole and 5-Amino-1MQ, sold as an iodide salt, 286 — so 300 mcg of AOD-9604 is about 165 nanomoles, while 2.5 mg of 5-Amino-1MQ iodide is about 8,740. That is roughly 53 times as many molecules for 8.3 times the mass. A 50 mg capsule is about 175,000 nanomoles. The salt matters too: the active cation is 55.6% of the iodide by mass, so a label that does not name its salt form leaves every figure uncertain by a factor of 1.8. None of these counts says anything about effect; the two act on unrelated targets.
The arithmetic per vial
Units on a U-100 syringe = milligrams ÷ concentration in mg/mL × 100.
| Compound | Vial and water | Concentration | 250 mcg | 300 mcg | 500 mcg | 2.5 mg | 5 mg |
|---|---|---|---|---|---|---|---|
| AOD-9604 | 2 mg + 1 mL | 2 mg/mL | 12.5 units | 15 | 25 | — | — |
| AOD-9604 | 5 mg + 2 mL | 2.5 mg/mL | 10 | 12 | 20 | — | — |
| AOD-9604 | 10 mg + 3 mL | 3.33 mg/mL | 7.5 | 9 | 15 | — | — |
| 5-Amino-1MQ | 50 mg + 3 mL | 16.7 mg/mL | — | — | — | 15 | 30 |
| 5-Amino-1MQ | 50 mg + 2 mL | 25 mg/mL | — | — | — | 10 | 20 |
| 5-Amino-1MQ | 100 mg + 2 mL | 50 mg/mL | — | — | — | 5 | 10 |
The draws come out in the same range of units because 5-Amino-1MQ vials hold ten to fifty times as much powder. A 5 mg AOD-9604 vial holds about 16 of the 300 mcg amounts; a 50 mg 5-Amino-1MQ vial holds 20 of the 2.5 mg amounts. The oral figures for 5-Amino-1MQ cannot be converted, because a capsule has no concentration. Mixing figures are on AOD-9604 reconstitution and 5-Amino-1MQ reconstitution; the same comparison against a third compound is on 5-Amino-1MQ vs MOTS-c and AOD-9604 vs MOTS-c.
Status
AOD-9604 is named in section S2.2.3 of the 2026 World Anti-Doping Agency Prohibited List, among growth hormone fragments (Tractatenblad 2026 no. 25, as recorded on this site's AOD-9604 vs MOTS-c page, read 2026-10-17). Its sponsor described it as self-affirmed "generally recognised as safe" for foods; this site found no record of it in FDA's GRAS notice inventory (2026-09-18). 5-Amino-1MQ has no regulatory record of any kind in the sources read.
What is not established
No study has compared the two or given them together. AOD-9604's human record is oral and intravenous, so the injected figures that circulate have no trial behind them; 5-Amino-1MQ has no human record at all, and converting its mouse figures to people is a convention whose own source warns against simple conversion. Medibact's AOD-9604 guide and 5-Amino-1MQ guide cover the compounds. Decisions about administering anything belong with a clinician.
Sources and dates
Opened 2026-10-26: DailyMed searches for 5-amino-1mq and aod-9604 (0 each); ClinicalTrials.gov v2 API searches for 5-amino-1MQ, AOD-9604 and AOD9604 (0 each); PubMed searches through NCBI E-utilities for 5-amino-1-methylquinolinium or 5-amino-1MQ (3: PMIDs 39067875, 35013352, 33645410) and AOD-9604 or AOD9604 (23); PubMed records for PMIDs 30753815, 29155147 and 11146367 (titles, journals, dates); PubChem CIDs 950107 and 71300630. From this site's pages with their read dates: the Stier, Vos and Kenley 2013 trial summary and the GRAS search (2026-09-18), the iodide molecular weight (PubChem CID 66522933, 2026-09-19), the vendor figures (2026-09-18) and the Prohibited List section (2026-10-17). Molecule-count and unit arithmetic by this site. Corrections go to the contact page.